Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

The patient’s grade 4 bullous pemphigoid emerges despite cabozantinib dose reduction, requiring high-dose corticosteroids and ...

Immunoinflammatory skin diseases are characterized by an imbalance in immune homeostasis, and their chronic inflammatory processes involve a complex regulatory network of CD4+ T cell differentiation.

We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...

While dupilumab improved urticaria activity, the researchers found its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab may be efficacious for children with eosinophilic esophagitis with prior STC treatment or prior IRIC to STCs.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a ...

In recent years, biologic agents have provided new directions for COPD treatment. Dupilumab, a humanized monoclonal antibody targeting IL-4Rα, has shown good efficacy in type 2 inflammation-related ...